Thiopurines in inflammatory bowel disease revisited

Florian Bär, Christian Sina, Klaus Fellermann*

*Corresponding author for this work
28 Citations (Scopus)


Although a great variety of new drugs have been introduced for the therapy of inflammatory bowel diseases so far, a definite cure of the disease is still out of scope. An anti-inflammatory approach to induce remission followed by maintenance therapy with immunosupres-sants is still the mainstay of therapy. Thiopurines comprising azathioprine and its active metabolite mercap-topurine as well as tioguanine, are widely used in the therapy of chronic active inflammatory bowel disease (IBD). Their steroid sparing potential and efficacy in remission maintenance are out of doubt. Unfortunately, untoward adverse events are frequently observed and may preclude further administration or be life threatening. This review will focus on new aspects of thiopurine therapy in IBD, its efficacy and safety.

Original languageEnglish
JournalWorld Journal of Gastroenterology
Issue number11
Pages (from-to)1699-1706
Number of pages8
Publication statusPublished - 21.03.2013


Dive into the research topics of 'Thiopurines in inflammatory bowel disease revisited'. Together they form a unique fingerprint.

Cite this